These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29773695)

  • 21. Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead-Sea.
    Harari M; Shani J; Hristakieva E; Stanimirovic A; Seidl W; Burdo A
    Int J Dermatol; 2000 Dec; 39(12):913-8. PubMed ID: 11168660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimation error of the body surface area in psoriasis: a comparative study of physician and computer-assisted image analysis (ImageJ).
    Yoo KH; Jeong GJ; Park JH; Park SH; Li KS
    Clin Exp Dermatol; 2022 Jul; 47(7):1298-1306. PubMed ID: 35187683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    Am J Clin Dermatol; 2017 Aug; 18(4):583-590. PubMed ID: 28342016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Pilot Study to Assess the Reliability of Digital Image-Based PASI Scores Across Patient Skin Tones and Provider Training Levels.
    Wu D; Lu X; Nakamura M; Sekhon S; Jeon C; Bhutani T; Liao W
    Dermatol Ther (Heidelb); 2022 Jul; 12(7):1685-1695. PubMed ID: 35727498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Objective assessment of psoriasis erythema for PASI scoring.
    Ahmad Fadzil MH; Ihtatho D; Affandi AM; Hussein SH
    Annu Int Conf IEEE Eng Med Biol Soc; 2008; 2008():4070-3. PubMed ID: 19163606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computer-aided measurement of psoriatic lesion area in a multicenter clinical trial--comparison to physician's estimations.
    Kreft S; Kreft M; Resman A; Marko P; Kreft KZ
    J Dermatol Sci; 2006 Oct; 44(1):21-7. PubMed ID: 16822654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician's Global Assessment, Psoriasis Area and Severity Index and Static Physician's Global Assessment.
    Simpson MJ; Chow C; Morgenstern H; Luger TA; Ellis CN
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1415-20. PubMed ID: 25917214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
    Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
    Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Observer-independent assessment of psoriasis-affected area using machine learning.
    Meienberger N; Anzengruber F; Amruthalingam L; Christen R; Koller T; Maul JT; Pouly M; Djamei V; Navarini AA
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1362-1368. PubMed ID: 31594034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study.
    Boehncke S; Salgo R; Garbaraviciene J; Beschmann H; Hardt K; Diehl S; Fichtlscherer S; Thaçi D; Boehncke WH
    J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1187-93. PubMed ID: 21241371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A quantitative technique for assessing the change in severity over time in psoriatic lesions using computer aided image analysis.
    Lu J; Kazmierczak E; Manton JH; Sinclair R
    Annu Int Conf IEEE Eng Med Biol Soc; 2013; 2013():2380-3. PubMed ID: 24110204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inter-observer reliability of the PASI in a clinical setting.
    Cabrera S; Chinniah N; Lock N; Cains GD; Woods J
    Australas J Dermatol; 2015 May; 56(2):100-2. PubMed ID: 25753553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synchronous balneophototherapy is effective for the different clinical types of psoriasis.
    Holló P; Gonzalez R; Kása M; Horváth A
    J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):578-81. PubMed ID: 16164712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature.
    Puzenat E; Bronsard V; Prey S; Gourraud PA; Aractingi S; Bagot M; Cribier B; Joly P; Jullien D; Le Maitre M; Paul C; Richard-Lallemand MA; Ortonne JP; Aubin F
    J Eur Acad Dermatol Venereol; 2010 Apr; 24 Suppl 2():10-6. PubMed ID: 20443995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment.
    Langley RG; Ellis CN
    J Am Acad Dermatol; 2004 Oct; 51(4):563-9. PubMed ID: 15389191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort.
    Walsh JA; McFadden M; Woodcock J; Clegg DO; Helliwell P; Dommasch E; Gelfand JM; Krueger GG; Duffin KC
    J Am Acad Dermatol; 2013 Dec; 69(6):931-7. PubMed ID: 24054760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity.
    van de Kerkhof PC; Kragballe K; Austad J; Berth-Jones J; Cambazard F; de la Brassinne M; Ljungberg A; Murphy G; Papp K; Wozel G
    Eur J Dermatol; 2006; 16(2):167-71. PubMed ID: 16581570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
    Armstrong AW; Betts KA; Sundaram M; Thomason D; Signorovitch JE
    J Am Acad Dermatol; 2016 Oct; 75(4):740-746. PubMed ID: 27476973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of Inter-Rater and Intra-Rater Variability in Psoriasis Area and Severity Index Assessment by Photographic Training.
    Youn SW; Choi CW; Kim BR; Chae JB
    Ann Dermatol; 2015 Oct; 27(5):557-62. PubMed ID: 26512170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.